Annual EBITDA
-$243.11 M
+$79.94 M+24.74%
31 December 2023
Summary:
Nektar Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$243.11 million, with the most recent change of +$79.94 million (+24.74%) on 31 December 2023. During the last 3 years, it has risen by +$149.54 million (+38.09%). NKTR annual EBITDA is now -133.01% below its all-time high of $736.37 million, reached on 31 December 2018.NKTR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$30.04 M
+$14.41 M+32.43%
30 September 2024
Summary:
Nektar Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$30.04 million, with the most recent change of +$14.41 million (+32.43%) on 30 September 2024. Over the past year, it has increased by +$8.26 million (+21.57%). NKTR quarterly EBITDA is now -103.04% below its all-time high of $988.28 million, reached on 30 June 2018.NKTR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$137.77 M
+$8.26 M+5.65%
30 September 2024
Summary:
Nektar Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$137.77 million, with the most recent change of +$8.26 million (+5.65%) on 30 September 2024. Over the past year, it has increased by +$117.91 million (+46.11%). NKTR TTM EBITDA is now -114.34% below its all-time high of $960.51 million, reached on 30 June 2018.NKTR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NKTR EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +24.7% | +21.6% | +46.1% |
| 3 y3 years | +38.1% | +73.5% | +68.2% |
| 5 y5 years | -133.0% | +64.2% | +62.8% |
NKTR EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +47.4% | -1.1% | +79.8% | at high | +71.0% |
| 5 y | 5 years | -133.0% | +47.4% | -1.1% | +79.8% | at high | +71.0% |
| alltime | all time | -133.0% | +47.4% | -103.0% | +79.8% | -114.3% | +71.0% |
Nektar Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$30.04 M(-32.4%) | -$137.77 M(-5.7%) |
| June 2024 | - | -$44.45 M(+49.7%) | -$146.03 M(+1.1%) |
| Mar 2024 | - | -$29.70 M(-11.6%) | -$144.43 M(-40.6%) |
| Dec 2023 | -$243.11 M(-24.7%) | -$33.59 M(-12.3%) | -$243.11 M(-4.9%) |
| Sept 2023 | - | -$38.29 M(-10.6%) | -$255.68 M(-4.2%) |
| June 2023 | - | -$42.85 M(-66.6%) | -$266.96 M(-28.3%) |
| Mar 2023 | - | -$128.37 M(+178.1%) | -$372.41 M(+15.3%) |
| Dec 2022 | -$323.04 M(-30.1%) | -$46.16 M(-6.9%) | -$323.04 M(-21.4%) |
| Sept 2022 | - | -$49.57 M(-66.6%) | -$410.97 M(-13.4%) |
| June 2022 | - | -$148.30 M(+87.7%) | -$474.57 M(+9.1%) |
| Mar 2022 | - | -$79.01 M(-41.1%) | -$434.79 M(-5.9%) |
| Dec 2021 | -$461.82 M(+17.6%) | -$134.09 M(+18.5%) | -$461.82 M(+6.6%) |
| Sept 2021 | - | -$113.17 M(+4.3%) | -$433.38 M(+3.9%) |
| June 2021 | - | -$108.53 M(+2.3%) | -$417.10 M(+10.4%) |
| Mar 2021 | - | -$106.04 M(+0.4%) | -$377.91 M(-3.8%) |
| Dec 2020 | -$392.65 M(+3.2%) | -$105.65 M(+9.0%) | -$392.65 M(+2.6%) |
| Sept 2020 | - | -$96.89 M(+39.8%) | -$382.69 M(+3.5%) |
| June 2020 | - | -$69.33 M(-42.6%) | -$369.60 M(-6.7%) |
| Mar 2020 | - | -$120.78 M(+26.2%) | -$396.19 M(+4.1%) |
| Dec 2019 | -$380.54 M(-151.7%) | -$95.69 M(+14.2%) | -$380.54 M(+2.8%) |
| Sept 2019 | - | -$83.80 M(-12.6%) | -$370.03 M(-0.1%) |
| June 2019 | - | -$95.93 M(-8.8%) | -$370.33 M(-151.9%) |
| Mar 2019 | - | -$105.13 M(+23.4%) | $713.87 M(-3.1%) |
| Dec 2018 | $736.37 M(-1923.6%) | -$85.18 M(+1.3%) | $736.37 M(-8.1%) |
| Sept 2018 | - | -$84.10 M(-108.5%) | $801.53 M(-16.6%) |
| June 2018 | - | $988.28 M(-1296.1%) | $960.51 M(-1411.1%) |
| Mar 2018 | - | -$82.63 M(+312.8%) | -$73.26 M(+81.4%) |
| Dec 2017 | -$40.38 M(-57.5%) | -$20.02 M(-126.7%) | -$40.38 M(-15.8%) |
| Sept 2017 | - | $74.88 M(-264.6%) | -$47.94 M(-68.4%) |
| June 2017 | - | -$45.50 M(-8.5%) | -$151.52 M(+8.3%) |
| Mar 2017 | - | -$49.75 M(+80.4%) | -$139.97 M(+47.2%) |
| Dec 2016 | -$95.12 M(+229.0%) | -$27.57 M(-3.9%) | -$95.12 M(-11.0%) |
| Sept 2016 | - | -$28.70 M(-15.5%) | -$106.92 M(+45.2%) |
| June 2016 | - | -$33.95 M(+593.7%) | -$73.62 M(-8.0%) |
| Mar 2016 | - | -$4.89 M(-87.6%) | -$80.04 M(+176.8%) |
| Dec 2015 | -$28.91 M(+953.8%) | -$39.37 M(-957.2%) | -$28.91 M(+22.7%) |
| Sept 2015 | - | $4.59 M(-111.4%) | -$23.56 M(-142.4%) |
| June 2015 | - | -$40.36 M(-187.3%) | $55.51 M(-27.3%) |
| Mar 2015 | - | $46.23 M(-235.9%) | $76.31 M(-2879.9%) |
| Dec 2014 | -$2.74 M(-97.4%) | -$34.02 M(-140.7%) | -$2.75 M(+142.7%) |
| Sept 2014 | - | $83.66 M(-527.6%) | -$1.13 M(-98.7%) |
| June 2014 | - | -$19.57 M(-40.4%) | -$87.34 M(-9.5%) |
| Mar 2014 | - | -$32.83 M(+1.3%) | -$96.52 M(-7.8%) |
| Dec 2013 | -$104.73 M(-15.1%) | -$32.40 M(+1172.6%) | -$104.73 M(-6.1%) |
| Sept 2013 | - | -$2.55 M(-91.1%) | -$111.49 M(-18.8%) |
| June 2013 | - | -$28.75 M(-29.9%) | -$137.23 M(+4.5%) |
| Mar 2013 | - | -$41.03 M(+4.8%) | -$131.30 M(+6.4%) |
| Dec 2012 | -$123.39 M(+14.5%) | -$39.16 M(+38.5%) | -$123.39 M(+7.3%) |
| Sept 2012 | - | -$28.28 M(+23.9%) | -$114.96 M(+10.2%) |
| June 2012 | - | -$22.82 M(-31.1%) | -$104.33 M(-6.4%) |
| Mar 2012 | - | -$33.13 M(+7.8%) | -$111.47 M(+3.4%) |
| Dec 2011 | -$107.79 M(+1055.0%) | -$30.73 M(+74.0%) | -$107.79 M(+16.1%) |
| Sept 2011 | - | -$17.66 M(-41.1%) | -$92.84 M(+21.2%) |
| June 2011 | - | -$29.96 M(+1.7%) | -$76.62 M(+91.3%) |
| Mar 2011 | - | -$29.45 M(+86.6%) | -$40.05 M(+329.2%) |
| Dec 2010 | -$9.33 M(-87.7%) | -$15.78 M(+994.0%) | -$9.33 M(-262.0%) |
| Sept 2010 | - | -$1.44 M(-121.8%) | $5.76 M(-133.4%) |
| June 2010 | - | $6.61 M(+417.1%) | -$17.26 M(-65.1%) |
| Mar 2010 | - | $1.28 M(-287.4%) | -$49.45 M(-34.7%) |
| Dec 2009 | -$75.72 M | -$682.00 K(-97.2%) | -$75.72 M(-491.1%) |
| Sept 2009 | - | -$24.46 M(-4.4%) | $19.36 M(+22.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | -$25.58 M(+2.4%) | $15.83 M(+15.2%) |
| Mar 2009 | - | -$24.99 M(-126.5%) | $13.74 M(+441.2%) |
| Dec 2008 | $2.54 M(-135.7%) | $94.39 M(-437.2%) | $2.54 M(-105.3%) |
| Sept 2008 | - | -$27.99 M(+1.1%) | -$47.75 M(+50.0%) |
| June 2008 | - | -$27.67 M(-23.5%) | -$31.84 M(+28.9%) |
| Mar 2008 | - | -$36.19 M(-182.1%) | -$24.69 M(+246.8%) |
| Dec 2007 | -$7.12 M(-94.3%) | $44.10 M(-465.2%) | -$7.12 M(-91.4%) |
| Sept 2007 | - | -$12.08 M(-41.2%) | -$82.92 M(-4.2%) |
| June 2007 | - | -$20.53 M(+10.3%) | -$86.59 M(-27.6%) |
| Mar 2007 | - | -$18.62 M(-41.3%) | -$119.55 M(-4.9%) |
| Dec 2006 | -$125.72 M(-15.4%) | -$31.70 M(+101.3%) | -$125.72 M(-32.7%) |
| Sept 2006 | - | -$15.75 M(-70.6%) | -$186.70 M(-0.7%) |
| June 2006 | - | -$53.49 M(+115.8%) | -$188.03 M(+21.4%) |
| Mar 2006 | - | -$24.78 M(-73.3%) | -$154.84 M(+4.2%) |
| Dec 2005 | -$148.54 M(+171.3%) | -$92.67 M(+442.4%) | -$148.54 M(+116.0%) |
| Sept 2005 | - | -$17.09 M(-15.8%) | -$68.77 M(+4.1%) |
| June 2005 | - | -$20.30 M(+9.8%) | -$66.05 M(+6.2%) |
| Mar 2005 | - | -$18.48 M(+43.3%) | -$62.18 M(+13.1%) |
| Dec 2004 | -$54.76 M(+14.6%) | -$12.90 M(-10.2%) | -$54.96 M(-4.1%) |
| Sept 2004 | - | -$14.37 M(-12.5%) | -$57.34 M(+8.8%) |
| June 2004 | - | -$16.43 M(+45.8%) | -$52.69 M(+14.4%) |
| Mar 2004 | - | -$11.27 M(-26.2%) | -$46.07 M(-3.6%) |
| Dec 2003 | -$47.77 M(-41.1%) | -$15.28 M(+57.2%) | -$47.77 M(-16.5%) |
| Sept 2003 | - | -$9.72 M(-0.8%) | -$57.23 M(-14.5%) |
| June 2003 | - | -$9.80 M(-24.4%) | -$66.97 M(-11.0%) |
| Mar 2003 | - | -$12.97 M(-47.6%) | -$75.23 M(-7.2%) |
| Dec 2002 | -$81.11 M(+15.4%) | -$24.74 M(+27.1%) | -$81.11 M(+1.2%) |
| Sept 2002 | - | -$19.46 M(+7.7%) | -$80.17 M(-0.1%) |
| June 2002 | - | -$18.06 M(-4.2%) | -$80.25 M(-4.3%) |
| Mar 2002 | - | -$18.85 M(-20.8%) | -$83.87 M(-1.6%) |
| Dec 2001 | -$70.32 M(+30.9%) | -$23.79 M(+21.7%) | -$85.21 M(+7.5%) |
| Sept 2001 | - | -$19.55 M(-9.8%) | -$79.26 M(+4.8%) |
| June 2001 | - | -$21.68 M(+7.4%) | -$75.65 M(+9.2%) |
| Mar 2001 | - | -$20.19 M(+13.2%) | -$69.27 M(+8.5%) |
| Dec 2000 | -$53.72 M(+130.2%) | -$17.84 M(+11.9%) | -$63.85 M(+13.8%) |
| Sept 2000 | - | -$15.94 M(+4.2%) | -$56.09 M(+17.3%) |
| June 2000 | - | -$15.30 M(+3.6%) | -$47.82 M(+22.2%) |
| Mar 2000 | - | -$14.77 M(+46.6%) | -$39.12 M(+28.1%) |
| Dec 1999 | -$23.34 M(+26.9%) | -$10.08 M(+31.4%) | -$30.55 M(+12.1%) |
| Sept 1999 | - | -$7.67 M(+16.2%) | -$27.26 M(+7.4%) |
| June 1999 | - | -$6.60 M(+6.5%) | -$25.39 M(+11.5%) |
| Mar 1999 | - | -$6.20 M(-8.7%) | -$22.78 M(+4.2%) |
| Dec 1998 | -$18.39 M(+63.0%) | -$6.79 M(+17.1%) | -$21.86 M(+12.9%) |
| Sept 1998 | - | -$5.80 M(+45.3%) | -$19.37 M(+13.7%) |
| June 1998 | - | -$3.99 M(-24.4%) | -$17.03 M(+4.9%) |
| Mar 1998 | - | -$5.28 M(+22.7%) | -$16.23 M(+18.5%) |
| Dec 1997 | -$11.29 M(+9.6%) | -$4.30 M(+24.1%) | -$13.69 M(+3.8%) |
| Sept 1997 | - | -$3.46 M(+8.6%) | -$13.20 M(+6.1%) |
| June 1997 | - | -$3.19 M(+16.2%) | -$12.43 M(+1.5%) |
| Mar 1997 | - | -$2.74 M(-27.8%) | -$12.24 M(+5.6%) |
| Dec 1996 | -$10.30 M(+33.8%) | -$3.80 M(+40.7%) | -$11.60 M(+12.6%) |
| Sept 1996 | - | -$2.70 M(-10.0%) | -$10.30 M(+7.3%) |
| June 1996 | - | -$3.00 M(+42.9%) | -$9.60 M(+11.6%) |
| Mar 1996 | - | -$2.10 M(-16.0%) | -$8.60 M(-2.3%) |
| Dec 1995 | -$7.70 M(+48.1%) | -$2.50 M(+25.0%) | -$8.80 M(+1.1%) |
| Sept 1995 | - | -$2.00 M(0.0%) | -$8.70 M(+11.5%) |
| June 1995 | - | -$2.00 M(-13.0%) | -$7.80 M(+13.0%) |
| Mar 1995 | - | -$2.30 M(-4.2%) | -$6.90 M(+23.2%) |
| Dec 1994 | -$5.20 M | -$2.40 M(+118.2%) | -$5.60 M(+75.0%) |
| Sept 1994 | - | -$1.10 M(0.0%) | -$3.20 M(+52.4%) |
| June 1994 | - | -$1.10 M(+10.0%) | -$2.10 M(+110.0%) |
| Mar 1994 | - | -$1.00 M | -$1.00 M |
FAQ
- What is Nektar Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Nektar Therapeutics?
- What is Nektar Therapeutics annual EBITDA year-on-year change?
- What is Nektar Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Nektar Therapeutics?
- What is Nektar Therapeutics quarterly EBITDA year-on-year change?
- What is Nektar Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Nektar Therapeutics?
- What is Nektar Therapeutics TTM EBITDA year-on-year change?
What is Nektar Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of NKTR is -$243.11 M
What is the all time high annual EBITDA for Nektar Therapeutics?
Nektar Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is $736.37 M
What is Nektar Therapeutics annual EBITDA year-on-year change?
Over the past year, NKTR annual earnings before interest, taxes, depreciation & amortization has changed by +$79.94 M (+24.74%)
What is Nektar Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of NKTR is -$30.04 M
What is the all time high quarterly EBITDA for Nektar Therapeutics?
Nektar Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $988.28 M
What is Nektar Therapeutics quarterly EBITDA year-on-year change?
Over the past year, NKTR quarterly earnings before interest, taxes, depreciation & amortization has changed by +$8.26 M (+21.57%)
What is Nektar Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of NKTR is -$137.77 M
What is the all time high TTM EBITDA for Nektar Therapeutics?
Nektar Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $960.51 M
What is Nektar Therapeutics TTM EBITDA year-on-year change?
Over the past year, NKTR TTM earnings before interest, taxes, depreciation & amortization has changed by +$117.91 M (+46.11%)